Prise en charge primaire des cancers de l’endomètre : recommandations SFOG-CNGOF

Querleu, Denis; Daraı̈, Émile; Lécuru, Fabrice; Rafii, Arash; Chéreau, E.; Collinet, Pierre; Crochet, Patrice; Marret, H.; Mery-Lamarche, Eliane; Thomas, Laurence; Villefranque, Vincent; Floquet, Anne

doi:10.1016/j.gofs.2017.10.008

Cited by 17 publications

(15 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In French recommendations published in 2017, VB is recommended in IR group to reduce vaginal vault recurrence [12]. Our results do not support this proposition as we did not observe any improvement of RFS or OS in this group of patients when undertaking VB.…”

Section: Discussioncontrasting

confidence: 80%

“…Overall recurrence rate differed between HIR group (16%) and IR group (9%) (p<0.01). Nevertheless, in this study, vaginal vault and central pelvic recurrence concerned only 1% of patient in IR group and 3% in the HIR group whatever the adjuvant therapy undertaken, confirming that local recurrence is rare and justifying the current debate in national [812] and international [4] recommendations concerning the indication of VB in those populations.…”

Section: Discussionsupporting

confidence: 71%

See 1 more Smart Citation

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

et al. 2019

View full text Add to dashboard Cite

Objective According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS). Methods Data of 191 patients with IR and HIR EC who underwent primary surgery with or without VB and no other adjuvant treatment between 2000 and 2016 were extracted from the FRANCOGYN database. Rate of local recurrence, OS and local RFS in these two groups were compared using the Kaplan-Meier method. Results The number of patients with IR and HIR EC were 118 and 73 respectively. VB was used in 92 patients in IR group and 43 in HIR group. Median follow-up was 22 months. In the HIR group, the local recurrence rate was significantly higher in the no adjuvant therapy group in comparison with the VB group (16.7% and 0% respectively, p=0.02). There was also a significant improvement in local RFS (p=0.01) in VB group. In IR EC, there is no significant difference on local recurrence rate (4.2% and 3.2%, respectively, p=1.00) or local RFS (p=0.54) between the two groups. Conclusions VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.

show abstract

Section: Discussioncontrasting

confidence: 80%

Section: Discussionsupporting

confidence: 71%

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We were surprised by the initial FP rate of 10%, which was comparable across centers. Indeed, according to the new recommendations of the French Society of Gynecological Oncology (SFOG), 10% of patients would have been wrongly irradiated in the para-aortic area if no PAL had been performed [6]. We therefore decided to have these FDG-PET/CT reread by the nuclear physician at each center.…”

Section: Overall Performancementioning

confidence: 99%

“…Its therapeutic impact on survival is currently a source of debate [5]. Knowledge of the pelvic and paraaortic lymph node status influences the therapeutic decision through the indication or not of more or less extensive radiotherapy and systemic treatment [6]. Lymphadenectomy is currently the "gold standard" for the evaluation of lymph node involvement in endometrial cancer.…”

Section: Introductionmentioning

confidence: 99%

FDG-PET/CT and Para-Aortic Staging in Endometrial Cancer. A French Multicentric Study

Sallée

Margueritte

Gouy

et al. 2021

JCM

View full text Add to dashboard Cite

Background: FDG-PET/CT is a noninvasive examination that could be helpful for the management of endometrial cancer. The aim of this study was to evaluate the performance of FDG-PET/CT in assessing para-aortic lymph-node involvement in high-risk endometrial cancer. Methods: We performed a retrospective multicenter study including all patients who had a high-risk endometrial cancer with a preoperative FDG-PET/CT and a para-aortic lymphadenectomy (PAL) between 2009 and 2019. The main objective was to evaluate the overall performance of FDG-PET/CT. The secondary objectives were to evaluate its performances according to the histological type and according to FDG-PET/CT date (before or after hysterectomy), and to compare its overall performance with that of the MRI scan. Results: We included 200 patients from six different centers. After the false positive FDG-PET/CT was reread by nuclear physicians, FDG-PET/CT had a sensitivity of 61.8%, a specificity of 89.7%, a positive predictive value of 69.4%, a negative predictive value of 86.1%, and an AUC of 0.76. There were no statistically significant differences in the performances according to either histological type and or FDG-PET/CT date. The sensitivity of FDG-PET/CT was better than that of MRI (p < 0.01), but the specificity was not (p = 0.82). Conclusion: Currently, FDG-PET/CT alone cannot replace PAL for the lymph node evaluation of high-risk endometrial cancers. It seems essential to reread it in multidisciplinary meetings before validating the therapeutic management of patients, particularly in the case of isolated para-aortic involvement.

show abstract

“…Les recommandations Françaises pour le diagnostic et la prise en charge des cancers de l’endomètre ont été réactualisées en 2017 avec la collaboration du collège national des gynécologues obstétriciens (CNGOF) et la société française d’oncologie gynécologique (SFOG) [4] d’après les dernières recommandations de l’Institut National du Cancer en 2010 [5] ainsi que des recommandations d’une conférence de consensus européenne organisée par les sociétés d’oncologie médicale, de radiothérapie et d’oncologie gynécologique publiées en 2016 [2] . La prise en charge initiale des cancers de l’endomètre de type 2 localisés est chirurgicale.…”

Section: Introductionunclassified

Évaluation de l’application des recommandations des cancers de l’endomètre de type 2 : étude rétrospective multicentrique

et al. 2020

View full text Add to dashboard Cite

Introduction Les carcinomes de l’endomètre de type 2 sont des cancers peu fréquents et de mauvais pronostique. Il existe très peu d’étude analysant leur prise en charge. L’objectif de l’étude était d’étudier la prise en charge des carcinomes de type 2 dans nos centres en évaluant l’application des recommandations. Matériel et méthode Il s’agit d’une étude multicentrique rétrospective enregistrant les cancers de l’endomètre de type 2 pris en charge de janvier 2009 à décembre 2019. Les analyses ont été adaptées aux dernières recommandations françaises appliquées par rapport à l’année de prise en charge. Résultats Soixante-quatorze carcinomes de type 2 ont été analysés dans dix centres: 34 carcinosarcomes (45,9 %), 29 carcinomes séreux (39,2 %), neuf carcinomes à cellules claires (12,2 %) et deux carcinomes indifférenciés (2,7 %). Lors de la prise en charge initiale, les recommandations étaient appliquées dans 45,9 % des cas. Le principal motif de non-application des recommandations était la non-réalisation d’une stadification ganglionnaire chirurgicale pour 20 patientes (57,1 %). Lors de la prise en charge adjuvante, les recommandations étaient appliquées dans 37,8 % des cas. Le principal motif de non-application des recommandations était la non-réalisation d’une restadification ganglionnaire chirurgicale ou radiologique pour 25 patientes (67,6 %). Discussion L’applicabilité des recommandations pour la prise en charge des carcinomes de type 2 reste difficile en raison de l’âge élevé et des comorbidités des patientes notamment pour la réalisation d’une stadification chirurgicale ganglionnaire pelvienne et lombo-aortique. L’utilisation de nouvelles techniques de stadification permettrait de mieux sélectionner les indications de curages ganglionnaires.

show abstract

Prise en charge primaire des cancers de l’endomètre : recommandations SFOG-CNGOF

Cited by 17 publications

References 104 publications

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

Impact of vaginal brachytherapy in intermediate and high-intermediate risk endometrial cancer: a multicenter study from the FRANCOGYN group

FDG-PET/CT and Para-Aortic Staging in Endometrial Cancer. A French Multicentric Study

Évaluation de l’application des recommandations des cancers de l’endomètre de type 2 : étude rétrospective multicentrique

Contact Info

Product

Resources

About